Clinical Trial Update: Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating etokimab (ANB020) for adults with peanut allergy has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Etokimab

Snippet

Sponsor: AnaptysBio, Inc. | Conditions: Peanut Allergy | Phase 2 | Status: COMPLETED | Results posted: 2023-07-27